Bortezomib for previously untreated multiple myeloma

References

• Sirohi B, Powles R. Multiple myeloma. Lancet363, 875–887 (2004).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N. Engl. J. Med.364, 1046–1060 (2011).
   PubMed Web of Science ®Google Scholar
• Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur. J. Cancer38, 99–166 (2002).
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin.55, 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc.78, 21–33 (2003).
   PubMed Web of Science ®Google Scholar
• Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood111, 2521–2526 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood111, 2516–2520 (2008).
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood114, 3139–3146 (2009).
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Mateos MV, Martínez-López J et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J. Clin. Oncol.26, 5775–5782 (2008).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ Multiple Myeloma (V.1. 2008) (2008).
   Google Scholar
• Hideshima T, Richardson P, Chauhan D et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res.61, 3071–3076 (2001).
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl Acad. Sci. USA99, 14374–14379 (2002).
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V et al. Biologic sequelae of nuclear factor κ B blockade in multiple myeloma: therapeutic applications. Blood99, 4079–4086 (2002).
   PubMed Web of Science ®Google Scholar
• Keats JJ, Fonseca R, Chesi M et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell12, 131–144 (2007).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Richardson P et al. NF κ B as a therapeutic target in multiple myeloma. J. Biol. Chem.277, 16639–16647 (2002).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Ikeda H, Chauhan D et al. Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells. Blood114, 1046–1052 (2009).
   PubMed Web of Science ®Google Scholar
• VELCADE (bortezomib) for injection, prescribing information. Millenium Pharmaceuticals Inc., MA, USA (2009).
   Google Scholar
• Moreau P, Coiteux V, Hulin C et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica93, 1908–1911 (2008).
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosickiet S et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, Phase III, non-inferiority study. Lancet125, 431–440 (2011).
   Google Scholar
• Bannerman B, Xu L, Jones M et al. Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother. Pharmacol. DOI: 10.1007/s00280-011-1591-2 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Jagannath S, Barlogie B, Berenson JR et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer103, 1195–1200 (2005).
   PubMed Web of Science ®Google Scholar
• Golden EB, Lam PY, Kardosh A et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood113, 5927–5937 (2009).
   PubMed Web of Science ®Google Scholar
• Perrone G, Hideshima T, Ikeda H et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia23, 1679–1686 (2009).
   PubMed Web of Science ®Google Scholar
• Jagannath S, Durie BG, Wolf J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br. J. Haematol.129, 776–783 (2005).
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Leleu X et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM Phase II study. Haematologica91, 1498–1505 (2006).
   PubMed Web of Science ®Google Scholar
• Rosiñol L, Oriol A, Mateos MV et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J. Clin. Oncol.25, 4452–4458 (2007).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Xie W, Mitsiades C et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy and molecular correlations with response and neuropathy. J. Clin. Oncol.27, 3518–3525 (2009).
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Jacobus S, Vesole DH et al. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia24, 1406–1411 (2010).
   PubMed Web of Science ®Google Scholar
• Boccadoro M, Marmont F, Tribalto M et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J. Clin. Oncol.9, 444–448 (1991).
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Pegourie B et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood107, 1292–1298 (2006).
   PubMed Web of Science ®Google Scholar
• Blade J, San Miguel JF, Fontanillas M et al. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol. J.2, 272–278 (2001).
   PubMedGoogle Scholar
• Yang HH, Vescio R, Schenkein D, Berenson JR. A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, Velcade) and melphalan in patients with relapsed or refractory multiple myeloma. Clin. Lymphoma4, 119–122 (2003).
   PubMedGoogle Scholar
• Berenson JR, Yang HH, Sadler K et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J. Clin. Oncol.24, 937–944 (2006).
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernández JM, Hernández MT et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter Phase I/II study. Blood108, 2165–2172 (2006).
   PubMed Web of Science ®Google Scholar
• San Miguel J, Schlag R, Khuageva N et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med.359, 906–917 (2008).
   PubMed Web of Science ®Google Scholar
• Mateos MV, Richardson PG, Schlang R et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the Phase III VISTA trial. J. Clin. Oncol.28, 2259–2266 (2010).
   PubMed Web of Science ®Google Scholar
• De la Rubia J, Sanz MA. Treatment of multiple myeloma in the elderly: realities and hopes. Leuk. Lymphoma52, 9–14 (2011).
   PubMed Web of Science ®Google Scholar
• Mateos MV, Oriol A, Martínez J et al. Bortezomib, melphalan and prednisone versus bortezomib, thalidomide and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol.11, 934–941 (2010).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Rossi D et al. Bortezomib–melphalan–prednisone–thalidomide followed by maintenance with bortezomib–thalidomide compared with bortezomib–melphalan–prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J. Clin. Oncol.28, 5101–5109 (2010).
   PubMed Web of Science ®Google Scholar
• Bringhen S, Larocca A, de Rossi D et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood116, 4745–4753 (2010).
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Flinn IW, Rifkin RM et al. Phase IIIb UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients. Blood116, 619a (2010).
   Google Scholar
• Berenson JR, Yellin O, Woytowitz D et al. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. Eur. J. Hematol.82, 433–439 (2009).
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson PG, Barlogie B et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib. Haematologica91, 929–934 (2006).
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005–2001 Phase III trial. J. Clin. Oncol.28, 4621–4629 (2010).
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethasone over vincristine–doxorubicin–dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood106, 35–39 (2005).
   PubMed Web of Science ®Google Scholar
• Wang M, Giralt S, Delasalle K et al. Bortezomib in combination with thalidomide–dexamethasone for previously untreated multiple myeloma. Hematology12, 235–239 (2007).
   PubMed Web of Science ®Google Scholar
• Pineda-Roman M, Zangari M, van Rhee F et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia22, 1419–1427 (2008).
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F et al.; for the GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised Phase III study. Lancet376(9758), 2075–2085 (2010).
   PubMed Web of Science ®Google Scholar
• Rosiñol L, Cibeira MT, Mateos MV et al. A Phase III PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: Superiority of VTD (bortezomib/thalidomide/dexamethasone) over TD and VBMCP/VBAD plus bortezomib. Blood116, 307a (2010).
   PubMedGoogle Scholar
• Moreau P, Facon T, Attal M et al. Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007–02 study. J. Clin. Oncol.28(Suppl. 2), 8014a (2010).
   Google Scholar
• Mitsiades N, Mitsiades CS, Richardson PG et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood101, 2377–2380 (2003).
   PubMed Web of Science ®Google Scholar
• Ma MH, Yang HH, Parker K et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res.9, 1136–1144 (2003).
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Voorhees PM, Garcia RA et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood105, 3058–3065 (2005).
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P et al. Randomized Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma. Combination therapy improves time to progression. J. Clin. Oncol.25, 3892–3901 (2007).
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Brackett L, Kendall T et al. Combination therapy with Velcade, Doxil and dexamethasone (VDD) for patients with relapsed/refractory multiple myeloma (MM). Blood106, 5179a (2005).
   Google Scholar
• Popat R, Oakervee HE, Hallam S et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br. J. Haematol.141, 512–516 (2008).
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Kendall T, Al-Zoubi A et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin and dexamethasone in patients with newly diagnosed myeloma. J. Clin. Oncol.27, 5015–5022 (2009).
   PubMed Web of Science ®Google Scholar
• Baltathakis I, Terpos E, Delimpasi S et al. The combination of the proteasome inhibitor bortezomib with doxorubicin and dexamethasone (PAD regimen) as front-line therapy in newly diagnosed, high-risk multiple myeloma: results of a Phase II prospective multicenter study. Blood116, 3052a (2010).
   Google Scholar
• Palumbo A, Gay F, Falco P et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J. Clin. Oncol.28, 800–807 (2010).
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf I, van der Holt B et al. HOVON-65/GMMG-HD4 randomized Phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood116, 109a (2010).
   PubMedGoogle Scholar
• Richardson PG, Weller E, Lonial S et al. Lenalidomide, bortezomib and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood116, 679–686 (2010).
   PubMed Web of Science ®Google Scholar
• Roussel M, Avet-Loiseau H, Moreau P et al. Frontline therapy with bortezomib, lenalidomide and dexamethasone (VRD) induction followed by autologous stem cell transplantation, VRD consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma patients: primary results of the IFM 2008 Phase II study. Blood116, 624a (2010).
   Web of Science ®Google Scholar
• Ghosh N, Ye X, Ferguson A et al. Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma. Br. J. Haematol.125, 593–599 (2011).
   Google Scholar
• Reece DE, Piza Rodriguez G, Chen C et al. Phase I–II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J. Clin. Oncol.26, 4777–4783 (2008).
   PubMed Web of Science ®Google Scholar
• Reeder CB, Reece DE, Kukreti V et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a Phase II clinical trial. Leukemia23, 1337–1341 (2009).
   PubMed Web of Science ®Google Scholar
• Knop S, Liebisch P, Wandt H et al. Bortezomib, IV cyclophosphamide and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: results of an interim analysis of the German DSMM Xia trial. J. Clin. Oncol.27, 8516a (2009).
   Google Scholar
• De la Rubia J, Blade J, Lahuerta JJ et al. Effect of chemotherapy with alkylating agents on the yield of CD341 cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica91, 621–627 (2006).
   PubMed Web of Science ®Google Scholar
• Gasparetto C, Gockerman JP, Diehl LF et al. ‘‘Short course’’ bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. Biol. Blood Marrow Transplant.16, 70–77 (2009).
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Jagannath S, Vescio R et al. Phase II study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. Br. J. Haematol.148, 562–568 (2009).
   PubMed Web of Science ®Google Scholar
• Kumar SK, Flinn I, Noga V et al. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: Phase I results from the multicenter EVOLUTION study. Leukemia24, 1350–1356 (2010).
   PubMed Web of Science ®Google Scholar
• Kumar SK, Flinn I, Richardson PG et al. Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide and lenalidomide, for previously untreated multiple myeloma: results from the multi-center, randomized, Phase II EVOLUTION Study. Blood116, 621a (2010).
   Google Scholar
• Jakubowiak AJ, Reece DE, Hofmeister CC et al. Lenalidomide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed multiple myeloma: final results of Phase I/II MMRC trial. Blood114, 917a (2010).
   Google Scholar
• Ludwig H, Viterbo L, Greil R et al. Phase II study of bortezomib, thalidomide and dexamethasone +/- cyclophosphamide as induction therapy in previously untreated multiple myeloma (MM): safety and activity including evaluation of MRD. Haematologica95, 371a (2010).
   Google Scholar
• Pineda-Roman M, Zangari M, Haessler J et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br. J. Haematol.140, 625–634 (2008).
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N. Engl. J. Med.354, 1021–1030 (2006).
   PubMed Web of Science ®Google Scholar
• Nair B, van Rhee F, Shaughnessy JD et al. Superior results of Total Therapy 3 (2003–2033) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006–2066 with VRD maintenance. Blood115, 4168–4173 (2010).
   PubMed Web of Science ®Google Scholar
• Oakervee H, Popat R, Cavenagn JD. Use of bortezomib as induction therapy prior to stem cell, transplantation in frontline treatments of multiple myeloma: impact of stem cell harvesting and engraftment. Leuk. Lymphoma48, 1910–1921 (2007).
   PubMed Web of Science ®Google Scholar
• Moreau P, Hulin C, Marit G et al. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005–2001 trial. Leukemia24, 1233–1235 (2010).
   PubMed Web of Science ®Google Scholar
• Hollmig K, Stover J, Talamo G et al. Addition of bortezomib (Velcade) to high dose melphalan (Vel–Mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM). Blood104, 929a (2004).
   Google Scholar
• Roussel M, Moreau P, Huynh A et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a Phase II study of the Intergroupe Francophone du Myélome (IFM). Blood115, 32–37 (2009).
   PubMed Web of Science ®Google Scholar
• Lonial S, Kaufman J, Tighiouart M et al. A Phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin. Cancer Res.16, 5079–5086 (2010).
   PubMed Web of Science ®Google Scholar
• Ladetto M, Pagliano G, Ferrero S et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide and dexamethasone in patients with autografted myeloma. J. Clin. Oncol.28, 2077–2084 (2010).
   PubMed Web of Science ®Google Scholar
• Terragna C, Zamagni E, Petrucci MT et al. Molecular remission after bortezomib–thalidomide–dexamethasone compared with thalidomide–dexamethasone as consolidation therapy following double autologous transplantation for multiple myeloma: results of a qualitative and quantitative analysis. Blood116, 861a (2010).
   PubMedGoogle Scholar
• Sahebi F, Krishnan A, Farol L et al. High rate of complete remission (CR) and upgraded response with weekly maintenance bortezomib post single autologous peripheral stem cell transplant (PSCT) in patients with multiple myeloma. Results of a Phase II prospective study. Blood116, 2399a (2010).
   Google Scholar
• Abidi MH, Gul Z, Lum LG et al. A Phase I study of bortezomib during maintenance phase after high-dose melphalan and autologous stem cell transplantation in patients with multiple myeloma. Blood116, 2387a (2010).
   Google Scholar
• Roussel M, Dörr G, Vaillant W et al. Consolidation with bortezomib, thalidomide and dexamethasone after high dose therapy is feasible, safe and effective in de novo multiple myeloma patients who already received new drugs containing-induction regimen. Blood116, 3041a (2010).
   Google Scholar
• Stewart AK, Bergsagel PL, Greipp PR et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia21, 529–534 (2007).
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Leleu X, Roussel M et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol.28, 4630–4634 (2010).
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Neben K, Bertsch U et al. Bortezomib-based induction therapy followed by autologous stem cell transplantation and maintenance therapy with bortezomib improves outcome in myeloma patients with gain 1q21 and t(4;14) - a subgroup analysis of the HOVON-65/GMMG-HD4 trial. Blood116, 305a (2010).
   Google Scholar
• Reece DE, Rodriguez GP, Belch A et al. Prospective canadian trial in newly diagnosed multiple myeloma patients with t(4;14): bortezomib-based therapy without ASCT. Blood116, 1968a (2010).
   Google Scholar
• Mateos MV, Gutierrez NC, Paiva B et al. Clinical outcome according to both cytogenetic abnormalities (CA) detected by fluorescence in situ hibridization (FISH) and hyperdiploidy assessed by flow cytometry (FCM) in elderly newly diagnosed myeloma patients treated with a bortezomib based combination. Blood116, 309a (2010).
   PubMedGoogle Scholar
• Schwartz R, Davidson T. Pharmacology, pharmacokinetics and practical applications of bortezomib. Oncology (Williston Park)18(Suppl. 11), 14–21 (2004).
   PubMedGoogle Scholar
• Dimopoulos MA, Roussou M, Gavriatopoulou M et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib based regimens: identification of predictive factors. Clin. Lymphoma Myeloma9, 302–306 (2009).
   PubMedGoogle Scholar
• Chanan-Khan AA, Kaufman JL, Mehta J et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood109, 2604–2606 (2007).
   PubMed Web of Science ®Google Scholar
• Ludwig H, Drach J, Graf H et al. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica92, 1411–1414 (2007).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Richardson PG, Schlag R et al. VMP (bortezomib, melphalan and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function and results in reversal of renal impairment: cohort analysis of the Phase III VISTA study. J. Clin. Oncol.27, 6086–6093 (2009).
   PubMed Web of Science ®Google Scholar
• Mezzano SA, Barría M, Droguett MA et al. Tubular NF-κB and AP-1 activation in human proteinuric renal disease. Kidney Int.60, 1366–1377 (2001).
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Richardson PG, Sonneveld P et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX Phase III study. Leukemia22, 842–849 (2008).
   PubMed Web of Science ®Google Scholar
• Ludwig H, Adam Z, Hajek R et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results from a Phase II study. J. Clin. Oncol.28, 4635–4641 (2010).
   PubMed Web of Science ®Google Scholar
• Li J, Zhou DB, Jiao L et al. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Clin. Lymphoma Myeloma9, 394–398 (2009).
   PubMedGoogle Scholar
• Jagganath S, Barlogie B, Berenson J et al. A Phase II study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol.127, 165–172 (2004).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B. Berenson J et al. A Phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med.348, 2609–2617 (2003).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med.352, 2487–2489 (2005).
   PubMed Web of Science ®Google Scholar
• San Miguel J, Bladé J, Boccadoro M et al. Practical update on the use of bortezomib in the management of multiple myeloma. Oncologist11, 51–61 (2006).
   PubMed Web of Science ®Google Scholar
• Lonial S, Waller EK, Richardson PG et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood106, 3777–3784 (2005).
   PubMed Web of Science ®Google Scholar
• Mohty B, El-Cheikh J, Yakoub-Agha I et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica95, 311–319 (2010).
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood112, 1593–1599 (2008).
   PubMed Web of Science ®Google Scholar
• Broyl A, Corthals SL, Jongen JLM et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet11, 1057–1065 (2010).
   Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the Phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br. J. Haematol.144, 895–903 (2009).
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Sonneveld P, Schuster MW et al. Analysis of herpes zoster events among bortezomib-treated patients in the Phase III APEX study. J. Clin. Oncol.26, 4784–4790 (2008).
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin. Lymphoma Myeloma8, 237–240 (2008).
   PubMedGoogle Scholar
• Blanco B, Perez-Simon JA, Sanchez-Abarca LI et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood107, 3575–3583 (2006).
   PubMed Web of Science ®Google Scholar
• Nencioni A, Schwarzenberg K, Brauer KM et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood108, 551–558 (2006).
   PubMed Web of Science ®Google Scholar
• Nencioni A, Garuti A, Schwarzenberg K et al. Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur. J. Immunol.36, 681–689 (2006).
   PubMed Web of Science ®Google Scholar
• Peles S, Fisher NM, Devine SM et al. Bortezomib (Velcade) when given pretransplant and once weekly as consolidation therapy following high dose chemotherapy (HDCT) leads to high rates of reactivation of varicella zoster virus (VZV). Blood106, 3237a (2005).
   Google Scholar
• Uy GL, Goyal SD, Fisher NM et al. Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution Phase II study. Bone Marrow Transplant.43, 793–800 (2008).
   PubMed Web of Science ®Google Scholar
• Anaissie E, Nucci M. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin. Infect. Dis.49, 1211–1225 (2009).
   PubMed Web of Science ®Google Scholar
• Roodman GD. Pathogenesis of myeloma bone disease. Leukemia23, 435–441 (2009).
   PubMed Web of Science ®Google Scholar
• Zangari M, Esseltine D, Lee CK et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br. J. Haematol.131, 71–73 (2005).
   PubMed Web of Science ®Google Scholar
• Zangari M, Yaccoby S, Cavallo F et al. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin. Lymphoma Myeloma7, 109–114 (2006).
   PubMedGoogle Scholar
• Heider U, Kaiser M, Müller C et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur. J. Haematol.77, 233–238 (2006).
   PubMed Web of Science ®Google Scholar
• Giuliani N, Morandi F, Tagliaferri S et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood110, 334–338 (2007).
   PubMed Web of Science ®Google Scholar
• Terpos E, Heath DJ, Rahemtulla A et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br. J. Haematol.135, 688–692 (2006).
   PubMed Web of Science ®Google Scholar
• von Metzler I, Krebbel H, Hecht M et al. Bortezomib inhibits human osteoclastogenesis. Leukemia21, 2025–2034 (2007).
   PubMed Web of Science ®Google Scholar
• Reeder CB, Reece DE, Kukreti V et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood115, 3416–3417 (2010).
   PubMed Web of Science ®Google Scholar
• Kapoor P, Rajkumar SV, Dispenzieri A et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia4, 689–696 (2011).
   Google Scholar
• Palumbo A, Dimopoulos M, Delforge M, et al. A Phase III study to determine the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients ≥65 years with newly diagnosed multiple myeloma (NDMM). Haematologica95, 566a (2010).
   Google Scholar
• Rajkumar SV, Jacobus S, Callander NS et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet11, 29–37 (2010).
   Web of Science ®Google Scholar
• Stewart AK. Novel therapies for relapsed myeloma. Hematology Am. Soc. Hematol. Educ. Program.578–586 (2009).
   PubMedGoogle Scholar
• Khan ML, Stewart AK. Carfilzomib: a novel second-generation proteasome inhibitor. Future Oncol.7, 607–612 (2011).
   PubMed Web of Science ®Google Scholar